Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.

MLA

Honoré, N., et al. “Tumor-Agnostic Plasma Assay for Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 34, no. 12, Dec. 2023, pp. 1175–86. EBSCOhost, https://doi.org/10.1016/j.annonc.2023.09.3102.

APA

Honoré, N., van Marcke, C., Galot, R., Helaers, R., Ambroise, J., van Maanen, A., Mendola, A., Dahou, H., Marbaix, E., Van Eeckhout, P., Longton, E., Magremanne, M., Schmitz, S., Limaye, N., & Machiels, J.-P. (2023). Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 34(12), 1175–1186. https://doi.org/10.1016/j.annonc.2023.09.3102

Chicago

Honoré, N, C van Marcke, R Galot, R Helaers, J Ambroise, A van Maanen, A Mendola, et al. 2023. “Tumor-Agnostic Plasma Assay for Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 34 (12): 1175–86. doi:10.1016/j.annonc.2023.09.3102.